Vepesid Soft (etoposide): Reviews and patient testimonials
Medication indications
Vepesid Soft Capsules 50 mg and 100 mg
Recurrent or refractory testicular cancer
VEPESID is indicated in combination with other approved chemotherapeutic agents for the treatment of recurrent or refractory testicular cancer in adults.
Small cell lung cancer
VEPESID is indicated in combination with other approved chemotherapeutic agents for the treatment of small-cell lung cancer in adults.
Hodgkin's lymphoma
VEPESID is indicated in combination with other approved chemotherapeutic agents for the second line treatment of Hodgkin's lymphoma in adults.
Non-Hodgkin's lymphoma
VEPESID is indicated in combination with other approved chemotherapeutic agents for the treatment of relapsed or refractory non-Hodgkin's lymphoma in adults.
Acute myeloid leukaemia
VEPESID is indicated in combination with other approved chemotherapeutic agents for the treatment of relapsed or refractory acute myeloid leukaemia in adults.
Ovarian cancer
VEPESID is indicated in combination with other approved chemotherapeutic agents for the treatment of non-epithelial ovarian cancer in adults.
VEPESID is indicated for the treatment of platinum-resistant/refractory epithelial ovarian cancer in adults.
Route of administration: Oral
Molecule: etoposide
Patients' opinions on Vepesid Soft
In brief
General satisfaction level: Be the first to evaluate
Treatment's effectiveness: Be the first to evaluate
Ease of use: Be the first to evaluate
Adherence to prescription: Be the first to evaluate
Detected side effects: Be the first to evaluate
Improvement in the quality of life: Be the first to evaluate
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Never
10 = Always
1 = Not at all important
10 = Extremely important
1 = Not at all satisfied
10 = Extremely satisfied
Tips and advice of the community
Join Carenity and be the first to give your opinion on this medication.